Hatim Husain

Title(s)Associate Clinical Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Johns Hopkins University, Baltimore, MDMedical Oncology
    University of Southern California, Los Angeles, CAInternal Medicine
    Northwestern University, Chicago, ILDoctor of Medicine

    Collapse Overview 

    Collapse Research 
    Collapse Research Activities and Funding

    Description: I am a lung cancer medical oncologist at UCSD Moores Cancer Center pursuing a translational career in cancer therapeutic strategies in solid tumor malignancies. My passion is be involved in early drug development and my goal is to develop a translational laboratory for biomarker validation and drug testing in in vitro and in in vivo models that can form the basis for early phase clinical trials. I work very closely to characterize technology development in the circulating tumor DNA space and applications about its utility. Recent work has also involved in understanding mechanisms of resistance to anti-EGFR directed therapies and further understanding the mechanisms of immunogenic cell death in cancer cells.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Faculty Mentoring

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review. JCO Precis Oncol. 2024 Apr; 8:e2300644. Luo J, Florez N, Donnelly A, Lou Y, Lu K, Ma PC, Spira AI, Ryan D, Husain H. PMID: 38579193.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation. Clin Cancer Res. 2024 Mar 25. Rolfo CD, Madison RW, Pasquina LW, Brown DW, Huang Y, Hughes JD, Graf RP, Oxnard GR, Husain H. PMID: 38526394.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study. Transl Lung Cancer Res. 2023 Nov 30; 12(11):2229-2244. Zhang D, Liu X, Shen F, Zhao D, Shi Y, Zhang H, Liu J, Gao X, Chen M, Zhao J, Zhong W, Gao J, He M, Liu Y, Yang X, Qin J, Tang Y, Mu X, Gu Y, Zhang S, Chen X, Pang L, Meng Q, Guo Y, Zhang Y, Li W, Xing P, Cheng Y, Xin T, Li Q, Li Y, Chen J, Gao F, Jin B, Rossi A, Adachi H, Guerrera F, Husain H, Xu Y, Wang M. PMID: 38090527; PMCID: PMC10713260.
      View in: PubMed   Mentions:
    4. Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC. Clin Lung Cancer. 2024 01; 25(1):e58-e61. Lu K, Woodward BD, Boys J, Onaitis M, Husain H. PMID: 37852849.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Intracranial responses with selective KRAS-G12C inhibitors in non-small cell lung cancer. Transl Lung Cancer Res. 2023 Jun 30; 12(6):1335-1337. Lu K, Husain H. PMID: 37425398; PMCID: PMC10326777.
      View in: PubMed   Mentions: 1  
    6. Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study. JTO Clin Res Rep. 2023 Mar; 4(3):100459. Ji J, Aredo JV, Piper-Vallillo A, Huppert L, Rotow JK, Husain H, Stewart S, Cobb R, Wakelee HA, Blakely CM, Wong ML, Gubens MA, Madani MH, Digumarthy SR, McCoach C, Piotrowska Z, Neal JW, Riess JW. PMID: 36879929; PMCID: PMC9984841.
      View in: PubMed   Mentions: 9  
    7. Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples. JCO Precis Oncol. 2022 10; 6:e2200261. Husain H, Pavlick DC, Fendler BJ, Madison RW, Decker B, Gjoerup O, Parachoniak CA, McLaughlin-Drubin M, Erlich RL, Schrock AB, Frampton GM, Das Thakur M, Oxnard GR, Tukachinsky H. PMID: 36265119; PMCID: PMC9616642.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    8. Circulating tumor DNA accurately predicts disease progression and genotype alterations in postoperative adjuvant EGFR-TKI resistance: a case report. Transl Lung Cancer Res. 2022 Sep; 11(9):1961-1966. Zeng Z, Liu C, Deng S, Lin F, Husain H, Santarpia M, Liu L. PMID: 36248329; PMCID: PMC9554680.
      View in: PubMed   Mentions:
    9. A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer. Expert Opin Investig Drugs. 2022 Jul; 31(7):747-757. Cho BC, Goldberg SB, Kim DW, Socinski MA, Burns TF, Lwin Z, Pathan N, Ma WD, Masters JC, Cossons N, Wilner K, Nishio M, Husain H. PMID: 35657653.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    10. Intratumoral and intertumoral heterogeneity drives EGFR treatment considerations. J Thorac Dis. 2022 May; 14(5):1299-1301. Lu K, Husain H. PMID: 35693600; PMCID: PMC9186249.
      View in: PubMed   Mentions:
    11. The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study. Transl Lung Cancer Res. 2022 May; 11(5):776-785. Zhao Y, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Chen W, Luo Y, Wu L, Wang X, Nan K, Jin F, Dong J, Li B, Yamaguchi F, Breadner D, Nagano T, Tanaka F, Husain H, Li K, Han B. PMID: 35693290; PMCID: PMC9186169.
      View in: PubMed   Mentions: 3  
    12. High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience. JTO Clin Res Rep. 2022 Jun; 3(6):100328. Piper-Vallillo AJ, Rotow JK, Aredo JV, Shaverdashvili K, Luo J, Carlisle JW, Husain H, Muzikansky A, Heist RS, Rangachari D, Ramalingam SS, Wakelee HA, Yu HA, Sequist LV, Bauml JM, Neal JW, Piotrowska Z. PMID: 35637759; PMCID: PMC9142556.
      View in: PubMed   Mentions: 15  
    13. The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients. Transl Lung Cancer Res. 2022 Feb; 11(2):213-223. Yang Y, Shen S, Sun Y, Husain H, Zhou H, Lu S, Li Z. PMID: 35280306; PMCID: PMC8902092.
      View in: PubMed   Mentions: 5  
    14. Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes. NPJ Precis Oncol. 2021 Nov 29; 5(1):98. Palma G, Khurshid F, Lu K, Woodward B, Husain H. PMID: 34845311; PMCID: PMC8630042.
      View in: PubMed   Mentions: 26  
    15. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest. 2021 09; 160(3):1095-1107. Roosan MR, Mambetsariev I, Pharaon R, Fricke J, Husain H, Reckamp KL, Koczywas M, Massarelli E, Bild AH, Salgia R. PMID: 33878340; PMCID: PMC8449001.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    16. Applications of cell-free circulating tumor DNA detection in EGFR mutant lung cancer. J Thorac Dis. 2020 May; 12(5):2877-2882. Bulbul A, Leal A, Husain H. PMID: 32642200; PMCID: PMC7330324.
      View in: PubMed   Mentions: 5  
    17. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. Int J Cancer. 2020 03 01; 146(5):1359-1368. Ma F, Guan Y, Yi Z, Chang L, Li Q, Chen S, Zhu W, Guan X, Li C, Qian H, Xia X, Yang L, Zhang J, Husain H, Liao Z, Futreal A, Huang J, Yi X, Xu B. PMID: 31241775.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    18. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019 06; 570(7761):385-389. Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, Jensen SØ, Medina JE, Hruban C, White JR, Palsgrove DN, Niknafs N, Anagnostou V, Forde P, Naidoo J, Marrone K, Brahmer J, Woodward BD, Husain H, van Rooijen KL, Ørntoft MW, Madsen AH, van de Velde CJH, Verheij M, Cats A, Punt CJA, Vink GR, van Grieken NCT, Koopman M, Fijneman RJA, Johansen JS, Nielsen HJ, Meijer GA, Andersen CL, Scharpf RB, Velculescu VE. PMID: 31142840; PMCID: PMC6774252.
      View in: PubMed   Mentions: 405     Fields:    Translation:Humans
    19. Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer. EBioMedicine. 2019 May; 43:261-269. Wang Y, Zhao C, Chang L, Jia R, Liu R, Zhang Y, Gao X, Li J, Chen R, Xia X, Bulbul A, Husain H, Guan Y, Yi X, Xu J. PMID: 31031019; PMCID: PMC6562020.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    20. Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer. Cancer Res. 2019 02 15; 79(4):689-698. Murtuza A, Bulbul A, Shen JP, Keshavarzian P, Woodward BD, Lopez-Diaz FJ, Lippman SM, Husain H. PMID: 30718357.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    21. Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. Cancer Res. 2019 03 15; 79(6):1204-1213. Phallen J, Leal A, Woodward BD, Forde PM, Naidoo J, Marrone KA, Brahmer JR, Fiksel J, Medina JE, Cristiano S, Palsgrove DN, Gocke CD, Bruhm DC, Keshavarzian P, Adleff V, Weihe E, Anagnostou V, Scharpf RB, Velculescu VE, Husain H. PMID: 30573519; PMCID: PMC6481620.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    22. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2019 02 01; 37(4):278-285. Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV. PMID: 30550363; PMCID: PMC7001776.
      View in: PubMed   Mentions: 183     Fields:    Translation:Humans
    23. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol. 2018 11 01; 4(11):1527-1534. Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA. PMID: 30073261; PMCID: PMC6240476.
      View in: PubMed   Mentions: 307     Fields:    Translation:Humans
    24. Genomic and Proteomic Alterations in Desmoplastic Small Round Blue-Cell Tumors. JCO Precis Oncol. 2018; 2. Bulbul A, Shen JP, Xiu J, Tamayo P, Husain H. PMID: 32913982; PMCID: PMC7446341.
      View in: PubMed   Mentions: 7     Fields:    
    25. BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. JCO Precis Oncol. 2018; 2. Sheikine Y, Pavlick D, Klempner SJ, Trabucco SE, Chung JH, Rosenzweig M, Wang K, Velcheti V, Frampton GM, Peled N, Murray M, Chae YK, Albacker LA, Gay L, Husain H, Suh JH, Millis SZ, Reddy VP, Elvin JA, Hartmaier RJ, Dowlati A, Stephens P, Ross JS, Bivona TG, Miller VA, Ganesan S, Schrock AB, Ou SI, Ali SM. PMID: 32913992; PMCID: PMC7446447.
      View in: PubMed   Mentions: 20     Fields:    
    26. Systemic Treatment Options for Brain Metastases from Non-Small-Cell Lung Cancer. Oncology (Williston Park). 2018 04 15; 32(4):156-63. Bulbul A, Forde PM, Murtuza A, Woodward B, Yang H, Bastian I, Ferguson PK, Lopez-Diaz F, Ettinger DS, Husain H. PMID: 29684234.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    27. First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option? Front Oncol. 2018; 8:94. Bulbul A, Husain H. PMID: 29755953; PMCID: PMC5932412.
      View in: PubMed   Mentions: 8  
    28. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017 Dec; 49(12):1693-1704. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. PMID: 29106415; PMCID: PMC5709185.
      View in: PubMed   Mentions: 250     Fields:    Translation:HumansCells
    29. Desmoplastic Small Round Blue Cell Tumor: A Review of Treatment and Potential Therapeutic Genomic Alterations. Sarcoma. 2017; 2017:1278268. Bulbul A, Fahy BN, Xiu J, Rashad S, Mustafa A, Husain H, Hayes-Jordan A. PMID: 29225486; PMCID: PMC5687144.
      View in: PubMed   Mentions: 24  
    30. Cancer DNA in the Circulation: The Liquid Biopsy. JAMA. 2017 10 03; 318(13):1272-1274. Husain H, Velculescu VE. PMID: 28973237; PMCID: PMC5819336.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    31. Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. Oncotarget. 2017 Oct 27; 8(52):89848-89866. Hovelson DH, Liu CJ, Wang Y, Kang Q, Henderson J, Gursky A, Brockman S, Ramnath N, Krauss JC, Talpaz M, Kandarpa M, Chugh R, Tuck M, Herman K, Grasso CS, Quist MJ, Feng FY, Haakenson C, Langmore J, Kamberov E, Tesmer T, Husain H, Lonigro RJ, Robinson D, Smith DC, Alva AS, Hussain MH, Chinnaiyan AM, Tewari M, Mills RE, Morgan TM, Tomlins SA. PMID: 29163793; PMCID: PMC5685714.
      View in: PubMed   Mentions: 22     Fields:    
    32. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017 Aug 16; 9(403). Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, Speir S, Reinert T, Orntoft MW, Woodward BD, Murphy D, Parpart-Li S, Riley D, Nesselbush M, Sengamalay N, Georgiadis A, Li QK, Madsen MR, Mortensen FV, Huiskens J, Punt C, van Grieken N, Fijneman R, Meijer G, Husain H, Scharpf RB, Diaz LA, Jones S, Angiuoli S, Ørntoft T, Nielsen HJ, Andersen CL, Velculescu VE. PMID: 28814544; PMCID: PMC6714979.
      View in: PubMed   Mentions: 436     Fields:    Translation:HumansCells
    33. Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer. Mol Diagn Ther. 2017 08; 21(4):375-384. Yeung KT, More S, Woodward B, Velculescu V, Husain H. PMID: 28337711.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    34. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clin Cancer Res. 2017 Sep 01; 23(17):5101-5111. Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R. PMID: 28539465; PMCID: PMC5581668.
      View in: PubMed   Mentions: 79     Fields:    Translation:Humans
    35. Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology. Mol Cancer Ther. 2017 05; 16(5):948-955. Husain H, Nykin D, Bui N, Quan D, Gomez G, Woodward B, Venkatapathy S, Duttagupta R, Fung E, Lippman SM, Kurzrock R. PMID: 28468865.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCells
    36. Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. Clin Cancer Res. 2017 Aug 15; 23(16):4716-4723. Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, Weihe E, Park BH, Tewari M, Erlander MG, Cohen E, Lippman SM, Kurzrock R. PMID: 28420725; PMCID: PMC5737735.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    37. New Targets in Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am. 2017 02; 31(1):113-129. Park SJ, More S, Murtuza A, Woodward BD, Husain H. PMID: 27912827.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    38. Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer. Mol Cancer Ther. 2017 02; 16(2):265-272. Husain H, Scur M, Murtuza A, Bui N, Woodward B, Kurzrock R. PMID: 28159915.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    39. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clin Cancer Res. 2016 Nov 15; 22(22):5497-5505. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock R. PMID: 27185373.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCTClinical Trials
    40. Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer. Curr Treat Options Oncol. 2016 May; 17(5):25. Bui N, Woodward B, Johnson A, Husain H. PMID: 27085533.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    41. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. 2016 Mar 01; 7(9):9707-17. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Banks KC, Lanman RB, Talasaz A, Parker BA, Kurzrock R. PMID: 26848768; PMCID: PMC4891078.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCells
    42. An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014 May; 16(5):457-68. Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T, Diao L, Wang J, Wistuba II, Heymach JV, Lippman SM, Desgrosellier JS, Anand S, Weis SM, Cheresh DA. PMID: 24747441; PMCID: PMC4105198.
      View in: PubMed   Mentions: 213     Fields:    Translation:HumansAnimalsCells
    43. Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma. Laryngoscope. 2012 Dec; 122(12):2762-8. Husain H, Psyrri A, Markovic A, Rampias T, Pectasides E, Wang H, Slebos R, Yarbrough WG, Burtness B, Chung CH. PMID: 23086695; PMCID: PMC3574977.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    44. Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas. J Neurooncol. 2012 Aug; 109(1):123-7. Husain H, Savage W, Grossman SA, Ye X, Burger PC, Everett A, Bettegowda C, Diaz LA, Blair C, Romans KE, Holdhoff M. PMID: 22492246; PMCID: PMC3715051.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    45. ALK-targeted therapy for lung cancer: ready for prime time. Oncology (Williston Park). 2011 Jun; 25(7):597-601. Husain H, Rudin CM. PMID: 21888258.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    46. Radiotherapy in small-cell lung cancer. Oncology (Williston Park). 2010 Oct; 24(11):1047, 1049. Husain H, Hann C, Hales R. PMID: 21155457.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    47. Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer. Pharmacogenet Genomics. 2009 Feb; 19(2):95-102. Lurje G, Hendifar AE, Schultheis AM, Pohl A, Husain H, Yang D, Manegold PC, Ning Y, Zhang W, Lenz HJ. PMID: 18987561.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    48. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res. 2008 Dec 01; 14(23):7884-95. Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, El-Khoueiry A, Husain H, Wilson PM, Ladner RD, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ. PMID: 19047118.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    49. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics. 2008 Feb; 18(2):161-8. Lurje G, Zhang W, Yang D, Groshen S, Hendifar AE, Husain H, Nagashima F, Chang HM, Fazzone W, Ladner RD, Pohl A, Ning Y, Iqbal S, El-Khoueiry A, Lenz HJ. PMID: 18192902.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    Hatim's Networks
    Concepts (173)
    Derived automatically from this person's publications.
    Co-Authors (36)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department